Pedro Monsalve Diaz, MD
Retina Specialist · Chattanooga, TNNPI 1447710504
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,191 of the $3,497 with a category attached, or 62.7%. Alcon accounts for 67.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $1,943 and has fallen 91.8% since, to $160 in 2025.
Across 35 payments — averaging $99.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Apellis Pharmaceuticals, Inc.$209
- Regeneron Healthcare Solutions, Inc.$204
- Sight Sciences, Inc.$152
- Genentech USA, Inc.$149
- Amgen$139
- plus $298 from 4 others
What the payments were for
- Travel & lodging$1,20634%
- Food & beverage$2,19163%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 13 | $2,346 |
| Apellis Pharmaceuticals, Inc. | 5 | $209 |
| Regeneron Healthcare Solutions, Inc. | 7 | $204 |
| Sight Sciences, Inc. | 2 | $152 |
| Genentech USA, Inc. | 2 | $149 |
| Amgen | 1 | $139 |
| Astellas Pharma US Inc | 1 | $131 |
| AbbVie | 2 | $123 |
| Biotissue Holdings Inc. | 1 | $24 |
| Glaukos Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Centurion$403
- Clareon$250
- AcrySof IQ VIVITY IOL$149
- TEPEZZA$139
- Izervay$131
- Hydrus Microstent$125
- VABYSMO$120
- OMNI(R) SURGICAL SYSTEM (US)$109
How this compares
$3,497 in reported general payments places this provider in the 55th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 67 | $2,388 |
| MoxifloxacinMoxifloxacin Hcl | 34 | $669 |
| Ketorolac Tromethamine | 35 | $502 |
| Ofloxacin | 22 | $318 |
| ErythromycinErythromycin Base | 12 | $187 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $181 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chattanooga
- John StoneChattanooga$3K
- Randall FunderburkChattanooga$502
- Steve CharlesGermantown$5.8M
- Carl AwhNashville$1.3M
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- David ReichsteinNashville$114K
- Akshay ThomasNashville$108K
- Franco RecchiaNashville$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.